Gerresheimer Ag · XETR:GXI
Gerresheimer — Q1 2021 Earnings Presentation
22 slides from Gerresheimer's earnings presentation, Apr 8, 2021
Slide 1: Q1 2021 Results Presentation
Q1 2021 Results Presentation Dietmar Siemssen, CEO Bernd Metzner, CFO Duesseldorf, April 8, 2021
Slide 2: Disclaimer
Disclaimer − This presentation may contain certain forward-looking statements, including assumptions, opinions and views of the Company or cited from third party sources. Various known and unknown risks, uncertainties and other factors could cause the actual results, financial position, development
Slide 3: Achieving our Targets as One Gerresheimer
Achieving our Targets as One Gerresheimer CEO Dietmar Siemssen
Slide 4: Accelerating Growth Momentum
Accelerating Growth Momentum Key Take-Aways Q1 2021 − Q1 2021 good start to accelerate growth: − Organic revenue growth in-line with guidance: +3.1% core1 / +3.7% on group level − Adj. EBITDA margin core business: 19.0% (+80 basis points yoy) − Adj. EPS (FXN) surged +29.3% yoy − Steep increase in hi
Slide 5: One Gerresheimer
One Gerresheimer One Company With Great Capabilities and Opportunities − Living One Gerresheimer: we pulled down historical silos and formed a global team committed to our ambitious goals − Consequent implementation of formula G. We transform into a growth company as innovation leader and solution p
Slide 6: Success Story Biological Solutions
Success Story Biological Solutions Gx Biological Solutions a Good Showcase for One Gerresheimer Gx Biological Solutions: High Value Solutions are key growth driver – Serving biotech customers for FY 2021 and going forward with the whole Gerresheimer portfolio – as the go-to partner − cross-divisiona
Slide 7: Global Network is key for Innovation
Global Network is key for Innovation Connecting Competencies Worldwide Further center Syringes Center Innovation Center planned in Lohr of Excellence Technical Competence Smart Devices / Buende, Germany Center/Medical Systems Micro Pumps Wackersdorf, Germany Olten, Switzerland Technical Competence C
Slide 8: Set for Strong Q2 – Financial Update
Set for Strong Q2 – Financial Update CFO Dr. Bernd Metzner
Slide 9: Q1 2021: Good Start Into the Year
Q1 2021: Good Start Into the Year Operational View of key KPIs − Q1 2021 organic revenue growth in core business of 3.1% − Both divisions P&D and PPG showing good organic growth rates with significant revenue contribution from High Value Solutions − Headwinds in Moulded Glass cosmetics business in t
Slide 10: Outstanding Performance of all Divisions
Outstanding Performance of all Divisions Q1 2021: Divisional Performance and Highlights Organic growth yoy In EUR m Revenues Adjusted EBITDA Outstanding Adj. EBITDA performance +3.0% +12.6% — Significant revenue contribution from syringes 158 155 31 34 — Adj. EBITDA margin surged 2.1%-points to 22.0
Slide 11: Reconciliation Q1 2021
Reconciliation Q1 2021 Reported and Adjusted Financials Q1 2021 Q1 2020 YoY (FXN) In EUR m Reported Adjustment Adjusted Adjusted Adjusted Revenues 302.8 302.8 303.9 +3.7% EBITDA 52.1 2.1 54.2 51.1 +9.6% Depreciation & -32.9 9.1 -23.9 -27.3 Amortization EBIT 19.2 11.1 30.3 23.8 Financial Result -4.7
Slide 12: Free Cash Flow and Net Debt Improvement
Free Cash Flow and Net Debt Improvement Cash Flow and Financial Debt Performance In EUR m Q1 2021 Q1 2020 Change Adjusted EBITDA 54.2 51.1 +3.1 Change in net working capital -45.6 -81.7 +36.1 Net interest paid -1.9 -1.7 -0.2 Net taxes paid -8.9 -7.7 -1.2 Other -21.6 -5.1 -16.5 Cash flow from operati
Slide 13: 2021 Outlook
2021 Outlook CEO Dietmar Siemssen
Slide 14: Set Ambitious Targets and Achieve Them
Set Ambitious Targets and Achieve Them Growth Acceleration in the Mid-Term CAGR + 2% 2022 2019 2015 The transformation is ongoing 14 08/04/2021 Q1 2021 Earnings Presentation
Slide 15: Acceleration of Growth in Q2
Acceleration of Growth in Q2 Q2 2021 Projection and Outlook ▪ Solid mid-single digit ▪ High-single digit growth growth in Q2 expected Plastics & Primary ▪ Major revenue contribution ▪ Again impressive Devices Packaging Glass from Tubular Glass and quarter for syringes Gx® Elite Glass respectively Gx
Slide 16: Profitable Growth Accelerating
Profitable Growth Accelerating Guidance for FY 2021 and Mid-Term For Core Business1 (FXN) FY 2021 Mid-term Accelerate Mid-single High-single Revenue growth digit growth digit growth Further expand ~ 22 to 23% ~ 23% Adj. EBITDA margin Drive Adj. EPS growth ≥ 10% p.a. and shareholder value 1. The core
Slide 17: Appendix
Appendix 17 08/04/2021 Q1 2021 Earnings Presentation
Slide 18: Financial Calendar
Financial Calendar FINANCIAL CALENDAR June 9, 2021 Annual General Meeting 2021 July 13, 2021 Interim Report 2nd Quarter Results 2021 October 12, 2021 Publication 3rd Quarter Results 2021 18 08/04/2021 Q1 2021 Earnings Presentation
Slide 19: YoY Revenue & Organic Growth Reconciliation
YoY Revenue & Organic Growth Reconciliation (1 of 2) in EUR m organic growth rate +3.7% 304.8 303.9 0.8 0.9 302.8 -1.9 4.5 -10.0 4.6 +3.2% 293.9 +3.0% Q1 2020 FX Q1 2020 (FXN) P&D PPG GAT HQ, Cons. Q1 2021 (FXN) FX Q1 2021 19 08/04/2021 Q1 2021 Earnings Presentation
Slide 20: YoY EBITDA & Organic Growth Reconciliation
YoY EBITDA & Organic Growth Reconciliation (2 of 2) in EUR m organic growth rate 9.6% 55.3 54.2 2.5 -1.1 -2.6 3.9 1.0 51.1 -0.6 50.5 -9% Organic +13% Adj. EBITDA margin 19.3% Org. Adj. EBITDA margin core: 18.6% Q1 2020 FX Q1 2020 (FXN) P&D PPG GAT HQ, Cons. Q1 2021 (FXN) FX Q1 2021 20 08/04/2021 Q1
Slide 21: Improving Financial Headroom
Improving Financial Headroom Net Financial Debt & Adjusted EBITDA Leverage Net financial debt according to credit agreement in force Maturity Profile In EUR m Net Financial Debt 1,017 (EUR m)1 986 3.4 Promissory Loan 3.2 RCF Adj. EBITDA Leverage (x) 476 Feb-20 Feb-21 In EUR m Q1 2020 Q1 2021 Drawn p
Slide 22: serresheimer
serresheimer innovating for a better life